Skip to content
OpenCapital
Get started

Innovate VATE Life Sciences — Capital cash expenditures

Other segment segments

Infrastructure
$8.9M+117%
Spectrum
$600K+20.0%

Similar metrics at other companies

Danaher logo
DHRLife Sciences — Capital expenditures, gross
$27M-43.8%
Thermo Fisher Scientific logo
TMOLife Sciences Solutions — Purchases of property, plant and equipment
$20M-53.5%
GLW
GLWLife Sciences and Emerging Growth Businesses — CapEx
$5M-37.5%
STERIS logo
STEHealthcare and Life Sciences — Payments to Acquire Productive Assets
$32.65M-8.5%
Ashland logo
ASHLife Sciences — Segment Expenditure Addition To Long Lived Assets
$12.25M-19.7%
Ashland logo
ASHLife Sciences — Total Assets
$1.46B-22.4%

Other financials

Income statement

See full
Revenue$364.8M+33.0%
Gross profit$53.5M+17.6%
Operating income$10.0M+194%
Net income-$16.8M+31.4%
EPS (diluted)-$1.29+31.7%

Balance sheet

See full
Cash & equivalents$134.6M+297%
Total debt$1.4B+11.6%
Total equity-$256.3M-25.5%
Total assets$936.8M+7.9%

Cash flow

See full
Operating cash flow$45.5M+423%
CapEx$200.0K-95.7%
Free cash flow$45.3M+341%

Valuation

See full
Market cap$254.69M+274%
Enterprise value$1.52B+25.8%
P/S0.2×+0.1×

Profitability

See full
Gross margin15.5%-3.8pp
Operating margin2.6%-1.2pp
Net margin-4%0.0pp
FCF margin15.7%—

Returns & leverage

See full
Return on equity-8.1%—
Debt / equity1.7×—
Current ratio0.4×0.0×

Where this comes from

Reported directly by Innovate in its filing.

Tagged under the XBRL concept us-gaap:SegmentExpenditureAdditionToLongLivedAssets.

The official record: Innovate’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innovate's life sciences — capital cash expenditures.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innovate's life sciences — capital cash expenditures?
Innovate (VATE) reported life sciences — capital cash expenditures of $0 in Q1 2026.
How has Innovate's life sciences — capital cash expenditures changed year-over-year?
Innovate's life sciences — capital cash expenditures decreased by 100.0% year-over-year, from $100K to $0.
What is the long-term trend for Innovate's life sciences — capital cash expenditures?
Over 2 years (2023 to 2025), Innovate's life sciences — capital cash expenditures has grown at a -100.0% compound annual growth rate (CAGR), from $500K to $0.
What does life sciences — capital cash expenditures mean?
Refers to the actual cash outflows used by the Life Sciences segment to acquire, upgrade, or maintain physical assets such as property, plants, or equipment. It reflects the segment's investment in its long-term operational capacity.